T. Murray

发表

Preclinical profile of a dopamine D1 potentiator suggests therapeutic utility in neurological and psychiatric disorders

Hong Wang, Charles R. Yang, M. O'Neill, 2018, Neuropharmacology.

CNS SIRT3 Expression Is Altered by Reactive Oxygen Species and in Alzheimer’s Disease

S. Love, P. Kehoe, N. Balthasar, 2012, PloS one.

Nasal neuron PET imaging quantifies neuron generation and degeneration

F. A. Schroeder, H. Wey, M. Albers, 2017, The Journal of clinical investigation.

Fluoxetine-induced change in rat brain expression of brain-derived neurotrophic factor varies depending on length of treatment

M. O'Neill, T. Murray, T. Zetterström, 2004, Neuroscience.

Electrical and Network Neuronal Properties Are Preferentially Disrupted in Dorsal, But Not Ventral, Medial Entorhinal Cortex in a Mouse Model of Tauopathy

Jonathan T. Brown, M. Goodfellow, K. Phillips, 2016, The Journal of Neuroscience.

Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model

Ian F. Harrison, M. Lythgoe, E. Nagelhus, 2020, Brain : a journal of neurology.

Transcriptional Signatures of Tau and Amyloid Neuropathology

D. Collier, K. Moore, J. Mill, 2020, Cell reports.

Transcriptional Signatures of Progressive Neuropathology in Transgenic Models of Tau and Amyloid Pathology

D. Collier, K. Moore, J. Mill, 2019, SSRN Electronic Journal.

Transcriptional signatures of progressive neuropathology in transgenic tau and amyloid mouse models

D. Collier, K. Moore, J. Mill, 2019, bioRxiv.

The role of neuronal nicotinic acetylcholine receptors in acute and chronic neurodegeneration.

M. O'Neill, V. Lakics, S. Duty, 2002, Current drug targets. CNS and neurological disorders.

Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease

Emily C. Collins, Jack A. Wells, Mark F. Lythgoe, 2016, NeuroImage.

ARL 17477, a selective nitric oxide synthase inhibitor, with neuroprotective effects in animal models of global and focal cerebral ischaemia

Todd R. Wiernicki, M. O'Neill, D. Lodge, 2000, Brain Research.

Comparison of In Vivo and Ex Vivo MRI for the Detection of Structural Abnormalities in a Mouse Model of Tauopathy

Sébastien Ourselin, Emily C. Collins, M. Jorge Cardoso, 2017, Front. Neuroinform..

Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.

K. Whalley, P. Skolnick, M. O'Neill, 2004, European journal of pharmacology.

Imbalance in the response of pre- and post-synaptic components to amyloidopathy

M. Hutton, AndrewD . Randall, M. O'Neill, 2019, Scientific Reports.

Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau

P. Szekeres, M. Hutton, M. Goedert, 2016, The Journal of Neuroscience.

Conformation Determines the Seeding Potencies of Native and Recombinant Tau Aggregates

P. Szekeres, M. Hutton, M. Goedert, 2014, The Journal of Biological Chemistry.

A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity

Zeshan Ahmed, Tracey K. Murray, Markus Tolnay, 2014, Acta Neuropathologica.

Differential aberrant structural synaptic plasticity in axons and dendrites ahead of their degeneration in tauopathy

J. Isaac, M. Hutton, M. O'Neill, 2020, bioRxiv.

In vivo imaging of tau pathology using multi-parametric quantitative MRI

Sébastien Ourselin, Emily C. Collins, Marc Modat, 2015, NeuroImage.

Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models

P. Davies, M. Hutton, M. Citron, 2011, The Journal of Biological Chemistry.

Genome-wide RNAseq study of the molecular mechanisms underlying microglia activation in response to pathological tau perturbation in the rTg4510 tau transgenic animal model

Benjamin A. Logsdon, D. Collier, D. Airey, 2018, Molecular Neurodegeneration.

Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.

E. Nisenbaum, P. Szekeres, E. Karran, 2007, International review of neurobiology.

Synaptic alterations associated with disrupted sensory encoding in a mouse model of tauopathy

Jonathan T. Brown, M. Ashby, T. Murray, 2023, bioRxiv.

Optic nerve thinning and neurosensory retinal degeneration in the rTg4510 mouse model of frontotemporal dementia

Mark F. Lythgoe, Martina Bocchetta, Zeshan Ahmed, 2019, Acta Neuropathologica Communications.

Metabotropic Glutamate Receptors Modulate Exocytotic Tau Release and Propagation

E. Sher, G. Schiavo, Griffin J Fitzgerald, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Longitudinal changes in EEG power, sleep cycles and behaviour in a tau model of neurodegeneration

B. Eastwood, A. McCarthy, K. Wafford, 2020, Alzheimer's Research & Therapy.

In Vivo Imaging of Tau Pathology Using Magnetic Resonance Imaging Textural Analysis

Holly E. Holmes, James M. O'Callaghan, Ian F. Harrison, 2017, Front. Neurosci..

Tissue magnetic susceptibility mapping as a marker of tau pathology in Alzheimer's disease

Emily C. Collins, Jack A. Wells, Mark F. Lythgoe, 2017, NeuroImage.

Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy

A. Blockeel, M. O'Neill, F. Gastambide, 2017, Alzheimer's Research & Therapy.

Imaging the accumulation and suppression of tau pathology using multiparametric MRI

Marc Modat, Jack A. Wells, Mark F. Lythgoe, 2016, Neurobiology of Aging.

Increased Cerebral Vascular Reactivity in the Tau Expressing rTg4510 Mouse: Evidence against the Role of Tau Pathology to Impair Vascular Health in Alzheimer's Disease

Holly E. Holmes, James M. O'Callaghan, M. Lythgoe, 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease

M. O'Neill, S. Duty, T. Murray, 2002, Pharmacology Biochemistry and Behavior.

LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.

E. Nisenbaum, Charles R. Yang, M. Clay, 2006, CNS drug reviews.

LY503430, a Novel α-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional, Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson's Disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003, Journal of Pharmacology and Experimental Therapeutics.

Short Fibrils Constitute the Major Species of Seed-Competent Tau in the Brains of Mice Transgenic for Human P301S Tau

P. Szekeres, M. Hutton, M. Goedert, 2016, The Journal of Neuroscience.

LY 503430 , a Novel-Amino-3-hydroxy-5-methylisoxazole-4-propionic Acid Receptor Potentiator with Functional , Neuroprotective and Neurotrophic Effects in Rodent Models of Parkinson ’ s Disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003 .

LY 503430 , a novel AMPA receptor potentiator with functional , neuroprotective and neurotrophic effects in rodent models of Parkinson ’ s disease

E. Nisenbaum, K. Whalley, P. Skolnick, 2003 .

The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments.

M. Danhof, M. O'Neill, M. Merlini, 2008, Journal of pharmacological and toxicological methods.

Synthesis of (R,R)123I-QNB, a spect imaging agent for cerebral muscarinic acetylcholine receptors in-vivo

J. Mcculloch, D. Wyper, J. Owens, 1992 .

The AMPA Receptor Potentiator LY404187 Increases Cerebral Glucose Utilization and c-fos Expression in the Rat

J. Mcculloch, K. Whalley, M. O'Neill, 2004, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.